Table 3 Tail length (TL), %DNA, tail moment (TM) and olive tail moment (OTM) in the tumor, liver and kidney tissues of normal negative control group (G1), tumor control groups (G2), doxorubicin-treated group (G3) and groups treated with 100, 200 or 400 mg/kg of PSO nano-emulsion (G4, G5, G6) respectively.

TL

Tumour

–

2.70 ± 0.30^A

7.14 ± 0.74^B

6.27 ± 0.60^B

6.60 ± 0.41^B

6.86 ± 0.50^B

Liver

2.53 ± 0.36^A

2.15 ± 0.32^A

3.29 ± 0.45^AB

4.25 ± 0.57^B

3.30 ± 0.44^AB

3.48 ± 0.41^AB

Kidney

2.42 ± 0.34^A

4.25 ± 0.45^B

2.51 ± 0.31^A

2.27 ± 0.33^A

2.35 ± 0.33^A

3.17 ± 0.38^A

%DNA

Tumour

–

0.89 ± 0.12^A

3.74 ± 0.46^BC

2.50 ± 0.34^AB

12.08 ± 1.20^D

5.40 ± 0.63^C

Liver

7.32 ± 0.89^B

3.62 ± 0.33^A

5.63 ± 0.53^AB

3.92 ± 0.40^A

3.88 ± 0.42^A

14.48 ± 1.48^C

Kidney

2.91 ± 0.45^A

4.19 ± 0.47^AB

5.80 ± 0.64^B

5.49 ± 0.68^B

3.57 ± 0.40^A

7.61 ± 0.90^C

TM

Tumour

–

0.05 ± 0.02^A

0.36 ± 0.08^BC

0.22 ± 0.05^AB

0.91 ± 0.12^D

0.46 ± 0.08^C

Liver

0.41 ± 0.10^B

0.06 ± 0.02^A

0.26 ± 0.07^AB

0.25 ± 0.06^AB

0.17 ± 0.06^AB

0.98 ± 0.18^C

Kidney

0.08 ± 0.02^A

0.21 ± 0.05^A

0.18 ± 0.04^A

0.19 ± 0.05^A

0.08 ± 0.02^A

0.36 ± 0.09^B

OTM

Tumour

–

0.10 ± 0.02^A

0.38 ± 0.06^B

0.33 ± 0.06^B

0.78 ± 0.09^D

0.40 ± 0.05^B

Liver

0.51 ± 0.07^B

0.27 ± 0.03^A

0.54 ± 0.08^B

0.40 ± 0.05^AB

0.28 ± 0.04^A

0.87 ± 0.11^C

Kidney

0.16 ± 0.02^A

0.35 ± 0.05^BC

0.34 ± 0.04^BC

0.39 ± 0.05^CD

0.23 ± 0.04^AB

0.51 ± 0.06^D